Illumina has announced a strategic plan to boost its growth by focusing on new tools for streamlining DNA sequencing and expanding data analysis capabilities. The company aims for at least 10% total EPS growth over the next three years and targets 8%-9% sales growth by 2027. As part of its growth strategy, Illumina has partnered with the Broad Institute to develop new gene sequencing kits using CRISPR technology. The company also plans to execute share buybacks, which has been met with mixed reactions from investors. This strategic update marks the first since Jacob Thaysen became CEO last September. The strategy also taps into the Multiomics market and was outlined during the recent Strategy Update event.